Sharp Therapeutics Secures $10M Funding to Advance Gaucher Disease Treatment Toward Phase I Trials
核心洞察
Sharp Therapeutics announced a $10 million private placement funding round expected to close in Q1 2026, with major shareholder STX Partners (搜索) committing $4 million contingent on raising $6 million from other investors.
The company's lead compound '901 (搜索) demonstrated strong safety profiles in pre-IND dog studies at doses exceeding those used in earlier efficacy studies, positioning it as a potential front-line oral therapy for all forms of Gaucher disease (搜索).
Sharp filed a patent application for '901 and over 250 related analogs, while planning to submit for FDA Orphan Drug Designation in Q1 2026 as the compound advances toward Phase I clinical trials.
Sharp Therapeutics Corp (搜索). has announced a $10 million private placement funding round to advance its lead compound '901 (搜索) toward Phase I clinical trials for Gaucher disease (搜索), with the company's largest shareholder increasing its investment commitment based on promising preclinical data.
The Pittsburgh and Toronto-based biotech company expects the offering to close in the first quarter of 2026, with shares priced at not less than $2.50 per share. STX Partners (搜索), LLC, Sharp's largest shareholder, has committed to purchasing at least 1.6 million shares representing approximately $4 million in gross proceeds, contingent upon the company successfully raising at least $6 million from other current or new investors by March 15, 2026.
Strong Preclinical Safety Data Supports Investment
The increased funding commitment comes as Sharp reports significant progress on its GBA1 (搜索)-Gaucher program. Key pre-IND studies in dogs demonstrated that compound '901 (搜索) is well tolerated at doses far exceeding those used in earlier animal efficacy studies, according to the company's announcement.
"We continue to be impressed with the pharmaceutical properties of '901, which bodes well for it to potentially become front-line therapy in all forms of Gaucher disease (搜索)," said Scott Sneddon, Sharp's CEO. The compound is designed as an oral, CNS penetrant treatment for all forms of Gaucher disease as well as other lysosomal storage disorders (搜索).
John Hathaway, Managing Partner of STX Partners (搜索), expressed confidence in the company's scientific progress: "Sharp continues to deliver meaningful scientific progress, and we're increasing our investment commitment because we believe their best work is still ahead of them. The scientific breakthroughs we're seeing from this team represent exactly the kind of innovation that creates lasting value."
Intellectual Property and Regulatory Strategy
Sharp has filed a patent application with the US Patent and Trademark Office for '901 and over 250 related analogs, strengthening its intellectual property position around the compound. The company expects to file for Orphan Drug Designation for '901 with the US Food and Drug Administration in the first quarter of 2026.
The funding will enable Sharp to focus on generating key data in trials supporting the effectiveness of '901 as it prepares for Phase I clinical studies in Gaucher disease (搜索) patients.
Platform Technology for Genetic Diseases
Sharp Therapeutics operates as a preclinical-stage company developing first-choice small-molecule therapeutics for genetic diseases. The company's discovery platform combines novel high throughput screening technologies with compound libraries computationally optimized based on the physics and biology of cellular trafficking defects and allosteric activation of proteins.
This platform produces small molecule compounds designed to restore activity in mutated proteins, offering the potential to treat genetic disorders with conventional pill-based medicines rather than more complex therapeutic approaches.
The company also announced the granting of stock options to directors and officers, with 200,000 options granted to directors in May 2025 at an exercise price of $1.07 per share, and 225,000 options granted to an officer in December 2025 at $1.60 per share, both with 10-year terms and three-year vesting schedules.